QUERTON ENDOCRINOLOGIE
ActiveQUERTON ENDOCRINOLOGIE has been active since 2014 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €19k and a net result of €110k. Equity remains stable across the filed fiscal years (±1.5% per year). Its solvency ranks better than 17% of 16491 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Checked score
Score 2025
72
/ 100
Healthy
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability83▼-17
Solvency40▲+3
Growth58=
Track record100
Bankruptcy probability, 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €1k at 30 days acceptable
Liquidity tight (current ratio 1.06 against 1.01 in 2024; short-term debt: 85.4% and cash: 39.8% of total assets), and 85.4% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Eight signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 86
Relative position
BE, all sectors
reference
Sector 86
lower
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
14.6%
Return on assets
85.5%
Age of the figures
9 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 17% of 16491 sector peers (2025).
NBB · sector comparisonPosition among 16491 sector peers
Solvency
better than 17%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-03-2026, 126 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
126 d early
2024
30 d late
2023
30 d late
2022
19 d late
2021
on the day
2020
30 d early
2019
11 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
19-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€19k▲ 0.2%
2024 · €19k
2018: €20k
2019: €20k
2020: €20k
2021: €20k
2022: €19k
2023: €19k
2024: €19k
2018 → 2025
Total assets
€128k▼ 14.8%
2024 · €151k
2018: €133k
2019: €124k
2020: €122k
2021: €129k
2022: €116k
2023: €143k
2024: €151k
2018 → 2025
Net result
€110k▼ 16.9%
2024 · €132k
2018: €64k
2019: €80k
2020: €80k
2021: €91k
2022: €90k
2023: €121k
2024: €132k
2018 → 2025
Working capital
€7k▲ 297%
2024 · €2k
2018: €-5k
2019: €-10k
2020: €-19k
2021: €-6k
2022: €-25k
2023: €-5k
2024: €2k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€20k-€19k▼ 8.8%€19k▼ 0.2%€19k=€19k▲ 0.2%
Operating result€115k-€115k▼ 0.4%€157k▲ 36.5%€171k▲ 9.0%€191k▲ 12.1%
Net result€91k-€90k▼ 0.5%€121k▲ 34.6%€132k▲ 8.8%€110k▼ 16.9%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
After the dip in 2022 the operating result has climbed three years in a row; 2025 is 12% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €128k
Fixed assets
€12k▼ 29.8%
Current assets
€116k▼ 13.0%
Equity and liabilities €128k
Equity
€19k▲ 0.2%
Debt
€110k▼ 17.0%
The debt ratio falls from 87.6% to 85.4%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€198k▲
2024 · €178k
Cash flow
€116k▼
2024 · €139k
Solvency
14.6%▲
2024 · 12.4%
Current ratio
1.06▲
2024 · 1.01
Quick ratio
1.06▲
2024 · 1.01
Debt / equity
5.87▼
2024 · 7.08
ROE
587.1%▼
2024 · 708.3%
ROA
85.5%▼
2024 · 87.6%
Interest coverage
3.90▼
2024 · 2042.82
Debt
€110k▼
2024 · €132k
Debt ≤ 1 year
€110k▼
2024 · €132k
Income taxes
€31k▼
2024 · €39k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€151k€128k▼
Fixed assets21/28€17k€12k▼
Tangible fixed assets22/27€17k€12k▼
Furniture and vehicles24€17k€12k▼
Current assets29/58€134k€116k▼
Amounts receivable within one year40/41€52k€63k▲
Trade receivables40€48k€53k▲
Other amounts receivable41€4k€10k▲
Cash at bank and in hand54/58€80k€51k▼
Deferred charges and accrued income490/1€2k€2k▲
Equity and liabilities
Total equity and liabilities10/49€151k€128k▼
Equity10/15€19k€19k▲
Contributions10/11€19k€19k=
Profit (loss) carried forward14€37€74▲
Amounts payable17/49€132k€110k▼
Amounts payable within one year42/48€132k€110k▼
Other amounts payable47/48€132k€110k▼
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€7k€7k▼
Other operating charges640/8€566€583▲
Gross operating margin9900€178k€199k▲
Operating profit (loss)9901€171k€191k▲
Financial income75/76B€236€505▲
Recurring financial income75€236€505▲
Financial charges65/66B€87€51k▲
Recurring financial charges65€87€51k▲
Profit (loss) for the period before taxes9903€171k€141k▼
Income taxes67/77€39k€31k▼
Profit (loss) for the period9904€132k€110k▼
Profit (loss) for the period to be appropriated9905€132k€110k▼
Appropriation of the result
Profit (loss) to be appropriated9906€132k€110k▼
Profit (loss) brought forward from the previous period14P€39€37▼
Profit to be distributed694/7€132k€110k▼
Return on contributions (dividend)694€132k€110k▼
The notes to these accounts (9 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
27-03
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
30-08
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 30 days late
2024
31-12
Financial
Highest result since 2018net €132k ▲8.8%
Net result €132k, the highest in the series.
30-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 30 days late
2023
19-08
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 19 days late
2022
31-07
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
01-07
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
20-07
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
12-06
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
2018
05-07
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema
2017
26-06
NBB filing
Annual accounts filed
fiscal year 2016 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
5 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Profondeville · 1 establishment unit since 2014
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rue Léon François(B.V.) 505170 ProfondevilleGround area
1,236 m²
Building footprint
179 m²
Volume, LiDAR
835 m³
Parcel 92014A0186/00Y002, Wallonia · tallest building 7.1 m, ±1 floor. Linked by address, not a title deed.
1 establishment unit
Querton Endocrinologie
since 20142.232.260.010
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 92014A0186/00Y002 | Wallonia | 1,236 m² | 1 · 179 m² | 7.1 m · 1 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Recognitions · licences · registrations
Legal Entity Identifier
254900JAVE4EXEX0AM46
Similar companies · same sector, comparable size
DOCTEUR ELISE POZZA, OPHTALMOLOGUE
BE 0721.930.517
Tournai · Eq €19k
ALNADERM
BE 0716.933.037
Leuven · Eq €19k
Dr. Joke De Buck
BE 0713.517.251
Antwerpen · Eq €19k
DR. Wim Anné
BE 0543.534.946
Zedelgem · Eq €19k
DOCTEUR HAVAUX LAURENCE
BE 0716.633.129
Sint-Agatha-Berchem · Eq €19k
Of 16,627 companies in sector 86220 we hold annual accounts for 7,973. 3,057 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded15-05-2014
Fiscal year end31-12
Activities, NACEBEL
86220Specialist medical practice
Sources
Crossroads Bank for EnterprisesNational Bank · 12 filingsAddress and cadastre registers
Data from official sources, last processed on 18-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
2 entriesE-mail:lauquerton@hotmail.com
Phone:0495/45.49.83